Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy

Pertusati, Fabrizio ORCID: https://orcid.org/0000-0003-4532-9101, Serpi, Michaela ORCID: https://orcid.org/0000-0002-6162-7910 and McGuigan, Christopher ORCID: https://orcid.org/0000-0001-8409-710X 2011. Medicinal chemistry of nucleoside phosphonate prodrugs for antiviral therapy. Antiviral Chemistry and Chemotherapy 22 (5) , pp. 181-203. 10.3851/IMP2012

Preview

PDF - Accepted Post-Print Version Download (508kB) | Preview

Abstract

Considerable attention has been focused on the development of phosphonate-containing drugs for application in many therapeutic areas. However, phosphonate diacids are deprotonated at physiological pH and thus phosphonate-containing drugs are not ideal for oral administration, an extremely desirable requisite for the treatment of chronic diseases. To overcome this limitation several prodrug structures of biologically active phosphonate analogues have been developed. The rationale behind the design of such agents is to achieve temporary blockade of the free phosphonic functional group until their systemic absorption and delivery, allowing the release of the active drug only once at the target. In this paper, an overview of acyclic and cyclic nucleoside phosphonate prodrugs, designed as antiviral agents, is presented.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy Systems Immunity Research Institute (SIURI)
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Publisher:	Nucleus Global
ISSN:	2040-2066
Date of First Compliant Deposit:	30 March 2016
Last Modified:	17 Nov 2024 01:15
URI:	https://orca.cardiff.ac.uk/id/eprint/41440

Citation Data

Cited 84 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item